{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:22:58Z","timestamp":1768908178918,"version":"3.49.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cld.2023.05.006","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T16:28:18Z","timestamp":1688488098000},"page":"895-916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting Hepatitis B Virus DNA Using Designer Gene Editors"],"prefix":"10.1016","volume":"27","author":[{"given":"Henrik","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9859","key":"10.1016\/j.cld.2023.05.006_bib1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2023.05.006_bib2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/v13020180","article-title":"Hepatitis B virus DNA integration: in\u00a0vitro models for investigating viral Pathogenesis and persistence","volume":"13","author":"Tu","year":"2021","journal-title":"Viruses"},{"issue":"47","key":"10.1016\/j.cld.2023.05.006_bib3","doi-asserted-by":"crossref","first-page":"17862","DOI":"10.1073\/pnas.0608578103","article-title":"An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection","volume":"103","author":"Huang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.cld.2023.05.006_bib4","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/liv.12773","article-title":"Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma","volume":"35","author":"Tu","year":"2015","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.cld.2023.05.006_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.cld.2023.05.006_bib6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1515\/hsz-2017-0118","article-title":"Chronic viral hepatitis and its association with liver cancer","volume":"398","author":"Tu","year":"2017","journal-title":"Biol Chem"},{"issue":"9","key":"10.1016\/j.cld.2023.05.006_bib7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2036.2005.02453.x","article-title":"The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation","volume":"21","author":"van Zonneveld","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"5 Suppl","key":"10.1016\/j.cld.2023.05.006_bib8","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","article-title":"Benefits and risks of interferon therapy for hepatitis B","volume":"49","author":"Perrillo","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2023.05.006_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.006_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nmeth0508-374","article-title":"Unexpected failure rates for modular assembly of engineered zinc fingers","volume":"5","author":"Ramirez","year":"2008","journal-title":"Nat Methods"},{"issue":"18","key":"10.1016\/j.cld.2023.05.006_bib11","doi-asserted-by":"crossref","first-page":"10570","DOI":"10.1073\/pnas.95.18.10570","article-title":"FokI dimerization is required for DNA cleavage","volume":"95","author":"Bitinaite","year":"1998","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cld.2023.05.006_bib12","doi-asserted-by":"crossref","first-page":"636+","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat Rev Genet"},{"issue":"21","key":"10.1016\/j.cld.2023.05.006_bib13","doi-asserted-by":"crossref","first-page":"9283","DOI":"10.1093\/nar\/gkr597","article-title":"A\u00a0novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity","volume":"39","author":"Mussolino","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"10.1016\/j.cld.2023.05.006_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR\u2013Cas technologies and applications","volume":"20","author":"Pickar-Oliver","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.006_bib16","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.cld.2023.05.006_bib17","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/nmeth.3630","article-title":"Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements","volume":"12","author":"Thakore","year":"2015","journal-title":"Nat Methods"},{"issue":"10","key":"10.1016\/j.cld.2023.05.006_bib18","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nmeth.2600","article-title":"RNA-guided gene activation by CRISPR-Cas9-based transcription factors","volume":"10","author":"Perez-Pinera","year":"2013","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cell.2014.11.052","article-title":"Engineering complex synthetic transcriptional Programs with CRISPR RNA scaffolds","volume":"160","author":"Zalatan Jesse","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cld.2023.05.006_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2014.09.039","article-title":"A\u00a0protein-tagging system for signal amplification in gene expression and fluorescence imaging","volume":"159","author":"Tanenbaum","year":"2014","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.cld.2023.05.006_bib21","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gky222","article-title":"Paired D10A Cas9 nickases are sometimes more efficient than individual nucleases for gene disruption","volume":"46","author":"Gopalappa","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.cld.2023.05.006_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nbt.2675","article-title":"CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering","volume":"31","author":"Mali","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.cld.2023.05.006_bib23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/gtc.12437","article-title":"Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus","volume":"21","author":"Sakuma","year":"2016","journal-title":"Gene Cell"},{"issue":"6","key":"10.1016\/j.cld.2023.05.006_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nbt.2909","article-title":"Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification","volume":"32","author":"Guilinger","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"7603","key":"10.1016\/j.cld.2023.05.006_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"7785","key":"10.1016\/j.cld.2023.05.006_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib27","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2023.05.006_bib28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.omtn.2018.05.006","article-title":"One-vector system for multiplexed CRISPR\/Cas9 against hepatitis B virus cccDNA utilizing high-capacity adenoviral vectors","volume":"12","author":"Schiwon","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib29","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/s41598-019-38526-6","article-title":"Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR\/Cas9","volume":"9","author":"Kostyushev","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.cld.2023.05.006_bib30","doi-asserted-by":"crossref","first-page":"e0288821","DOI":"10.1128\/mbio.02888-21","article-title":"CRISPR-Cas9 targeting of hepatitis B virus covalently closed circular DNA generates transcriptionally active episomal variants","volume":"13","author":"Martinez","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.cld.2023.05.006_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcimb.2017.00091","article-title":"Removal of integrated hepatitis B virus DNA using CRISPR-cas9","volume":"7","author":"Li","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.006_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2006.11.010","article-title":"Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis","volume":"252","author":"Feitelson","year":"2007","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.cld.2023.05.006_bib33","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00018-019-03021-8","article-title":"Orthologous CRISPR\/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus","volume":"76","author":"Kostyushev","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cld.2023.05.006_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.cld.2023.05.006_bib35","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/hep4.2014","article-title":"Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy","volume":"6","author":"Murai","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2023.05.006_bib36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.cld.2023.05.006_bib37","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.7150\/ijbs.16064","article-title":"An effective molecular target site in hepatitis B virus S gene for Cas9 cleavage and mutational inactivation","volume":"12","author":"Li","year":"2016","journal-title":"Int J Biol Sci"},{"issue":"7","key":"10.1016\/j.cld.2023.05.006_bib38","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3390\/v13071344","article-title":"Improved specificity and safety of anti-hepatitis B virus TALENs using obligate heterodimeric FokI nuclease domains","volume":"13","author":"Smith","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/jmbi.2000.4481","article-title":"Structural organization of the hepatitis B virus minichromosome","volume":"307","author":"Bock","year":"2001","journal-title":"J\u00a0Mol Biol"},{"issue":"4","key":"10.1016\/j.cld.2023.05.006_bib40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1087057112463066","article-title":"Creation of a six-fingered artificial transcription factor that represses the hepatitis B virus HBx gene integrated into a human hepatocellular carcinoma cell line","volume":"18","author":"Zhao","year":"2012","journal-title":"J\u00a0Biomol Screen"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib41","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1186\/s12879-019-4436-y","article-title":"Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA","volume":"19","author":"Bloom","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.cld.2023.05.006_bib42","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hep4.1933","article-title":"Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing","volume":"6","author":"Zhou","year":"2022","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.cld.2023.05.006_bib43","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent inactivation of HBV genomes by CRISPR\/Cas9-Mediated non-cleavage base editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"10.1016\/j.cld.2023.05.006_bib44","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.bbrc.2016.08.152","article-title":"Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus","volume":"478","author":"Dreyer","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.cld.2023.05.006_bib45","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1136\/gutjnl-2015-310686","article-title":"The rs2296651 (S267F) variant on NTCP (<em>SLC10A1<\/em>) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B","volume":"65","author":"Hu","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.05.006_bib46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.omtm.2021.11.002","article-title":"Genetically edited hepatic cells expressing the NTCP-S267F variant are resistant to hepatitis B virus infection","volume":"23","author":"Uchida","year":"2021","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"issue":"10","key":"10.1016\/j.cld.2023.05.006_bib47","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41575-020-0296-6","article-title":"The evolution and clinical impact of hepatitis B virus genome diversity","volume":"17","author":"Revill","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2023.05.006_bib48","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.cld.2023.05.006_bib49","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/mt.2016.94","article-title":"Complete spectrum of CRISPR\/Cas9-induced mutations on HBV cccDNA","volume":"24","author":"Seeger","year":"2016","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib50","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1038\/srep13734","article-title":"CRISPR\/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X","volume":"5","author":"Karimova","year":"2015","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.cld.2023.05.006_bib51","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1099\/vir.0.000159","article-title":"Inhibition of hepatitis B virus by the CRISPR\/Cas9 system via targeting the conserved regions of the viral genome","volume":"96","author":"Liu","year":"2015","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.cld.2023.05.006_bib52","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2018.02.011","article-title":"Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus","volume":"152","author":"Liu","year":"2018","journal-title":"Antivir Res"},{"issue":"4","key":"10.1016\/j.cld.2023.05.006_bib53","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","article-title":"One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-Mediated genome engineering","volume":"153","author":"Wang","year":"2013","journal-title":"Cell"},{"issue":"6121","key":"10.1016\/j.cld.2023.05.006_bib54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-021-01487-4","article-title":"Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy","volume":"21","author":"Rasul","year":"2022","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nmeth.1539","article-title":"Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures","volume":"8","author":"Doyon","year":"2011","journal-title":"Nat Methods"},{"issue":"3","key":"10.1016\/j.cld.2023.05.006_bib57","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jmb.2010.10.043","article-title":"Creating designed zinc-finger nucleases with minimal cytotoxicity","volume":"405","author":"Ramalingam","year":"2011","journal-title":"J\u00a0Mol Biol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jmb.2010.04.060","article-title":"Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases","volume":"400","author":"Guo","year":"2010","journal-title":"J\u00a0Mol Biol"},{"issue":"19","key":"10.1016\/j.cld.2023.05.006_bib59","doi-asserted-by":"crossref","first-page":"11312","DOI":"10.1093\/nar\/gkab858","article-title":"Quantitative assessment of engineered Cas9 variants for target specificity enhancement by single-molecule reaction pathway analysis","volume":"49","author":"Bak","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cld.2023.05.006_bib60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jbiotec.2015.04.024","article-title":"Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection","volume":"208","author":"Liang","year":"2015","journal-title":"J\u00a0Biotechnol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.006_bib61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s13238-020-00699-6","article-title":"CAS9 is a genome mutator by directly disrupting DNA-PK dependent DNA repair pathway","volume":"11","author":"Xu","year":"2020","journal-title":"Protein Cell"},{"issue":"10","key":"10.1016\/j.cld.2023.05.006_bib62","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in\u00a0vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.cld.2023.05.006_bib63","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","article-title":"Non-viral CRISPR\/cas gene editing in\u00a0vitro and in\u00a0vivo enabled by synthetic nanoparticle Co-delivery of Cas9 mRNA and sgRNA","volume":"56","author":"Miller","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"issue":"15","key":"10.1016\/j.cld.2023.05.006_bib64","doi-asserted-by":"crossref","first-page":"14509","DOI":"10.1074\/jbc.M400349200","article-title":"Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor","volume":"279","author":"Segal","year":"2004","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"10.1016\/j.cld.2023.05.006_bib65","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nbt.3469","article-title":"A\u00a0dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice","volume":"34","author":"Yang","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.cld.2023.05.006_bib66","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A\u00a0multifunctional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nbt.3055","article-title":"In\u00a0vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9","volume":"33","author":"Swiech","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"7546","key":"10.1016\/j.cld.2023.05.006_bib68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In\u00a0vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cld.2023.05.006_bib69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-60761-753-2_14","article-title":"Quantification of zinc finger nuclease-associated toxicity","volume":"649","author":"Cornu","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.006_bib70","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nbt.4066","article-title":"A\u00a0highly specific SpCas9 variant is identified by in\u00a0vivo screening in yeast","volume":"36","author":"Casini","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"3\u20134","key":"10.1016\/j.cld.2023.05.006_bib71","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.funbio.2020.02.006","article-title":"Cas9HF1 enhanced specificity in Ustilago maydis","volume":"124","author":"Zuo","year":"2020","journal-title":"Fungal Biol"},{"issue":"6268","key":"10.1016\/j.cld.2023.05.006_bib72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"issue":"7699","key":"10.1016\/j.cld.2023.05.006_bib73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature26155","article-title":"Evolved Cas9 variants with broad PAM compatibility and high DNA specificity","volume":"556","author":"Hu","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib74","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-022-30228-4","article-title":"Genome editing in animals with minimal PAM CRISPR-Cas9 enzymes","volume":"13","author":"Vicencio","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.cld.2023.05.006_bib75","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/mt.2015.218","article-title":"Streptococcus thermophilus CRISPR-cas9 systems enable specific editing of the human genome","volume":"24","author":"M\u00fcller","year":"2016","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.cld.2023.05.006_bib76","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/mt.2016.8","article-title":"The Neisseria meningitidis CRISPR-cas9 system enables specific genome editing in mammalian cells","volume":"24","author":"Lee","year":"2016","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13059-015-0817-8","article-title":"Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications","volume":"16","author":"Friedland","year":"2015","journal-title":"Genome Biol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.006_bib78","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.molcel.2015.09.020","article-title":"DNase H activity of Neisseria meningitidis Cas9","volume":"60","author":"Zhang","year":"2015","journal-title":"Mol Cell"},{"issue":"19","key":"10.1016\/j.cld.2023.05.006_bib79","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1073\/pnas.1422340112","article-title":"Cas9-mediated targeting of viral RNA in eukaryotic cells","volume":"112","author":"Price","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"42","key":"10.1016\/j.cld.2023.05.006_bib80","doi-asserted-by":"crossref","first-page":"20959","DOI":"10.1073\/pnas.1818461116","article-title":"Francisella novicida Cas9 interrogates genomic DNA with very high specificity and can be used for mammalian genome editing","volume":"116","author":"Acharya","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.cld.2023.05.006_bib81","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/mt.2013.212","article-title":"An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases","volume":"22","author":"Chen","year":"2014","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.cld.2023.05.006_bib82","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2010.20","article-title":"Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs","volume":"18","author":"Cradick","year":"2010","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.cld.2023.05.006_bib83","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.cld.2023.05.006_bib84","doi-asserted-by":"crossref","first-page":"198191","DOI":"10.1016\/j.virusres.2020.198191","article-title":"Development of an in vivo delivery system for CRISPR\/Cas9-mediated targeting of hepatitis B virus cccDNA","volume":"290","author":"Kayesh","year":"2020","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib85","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1038\/s41598-017-05905-w","article-title":"Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9","volume":"7","author":"Kurihara","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.cld.2023.05.006_bib86","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.cld.2023.05.006_bib87","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1038\/s41598-017-07642-6","article-title":"ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells","volume":"7","author":"Scott","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2023.05.006_bib88","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting hepatitis B virus with CRISPR\/Cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"issue":"32","key":"10.1016\/j.cld.2023.05.006_bib89","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.3748\/wjg.v21.i32.9554","article-title":"Dual gRNAs guided CRISPR\/Cas9 system inhibits hepatitis B virus replication","volume":"21","author":"Wang","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.006_bib90","doi-asserted-by":"crossref","first-page":"e97579","DOI":"10.1371\/journal.pone.0097579","article-title":"AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cld.2023.05.006_bib91","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1134\/S0006297914020047","article-title":"Hepatitis B virus can be inhibited by DNA methyltransferase 3a via specific zinc-finger-induced methylation of the X promoter","volume":"79","author":"Xirong","year":"2014","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.cld.2023.05.006_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.665184","article-title":"Inhibition of hepatitis B virus by AAV8-derived CRISPR\/SaCas9 expressed from liver-specific promoters. Original research","volume":"12","author":"Yan","year":"2021","journal-title":"Front Microbiol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.006_bib93","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/gt.2015.2","article-title":"Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)\/CRISPR-associated Cas9 system to disrupt the hepatitis B virus","volume":"22","author":"Zhen","year":"2015","journal-title":"Gene Ther"},{"key":"10.1016\/j.cld.2023.05.006_bib94","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.virusres.2016.04.003","article-title":"CRISPR\/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse","volume":"217","author":"Zhu","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.cld.2023.05.006_bib95","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.omtm.2020.11.014","article-title":"CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice","volume":"20","author":"Stone","year":"2021","journal-title":"Molecular Therapy Methods Clinical Development"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:38Z","timestamp":1761069698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1089326123000661"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Hepatitis B Virus DNA Using Designer Gene Editors","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}